Tag: acute myelogenous leukemia
ASH 2020: Preclinical Models Identify CD74 as Potential Target for the...
Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial with STRO-001, a CD74-targeted...
Vadastuximab Talirine (SGN-CD33A) Combination Therapy Evaluates Safety and Activity for Patients...
A new phase I/II clinical trial of vadastuximab talirine, also known as SGN-CD33A; 33A (Seattle Genetics), in combination with azacitidine (Vidaza®; Celgene Corporation) in patients with...